Literature DB >> 32900772

Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease.

Israt S Alam1, Federico Simonetta2, Lukas Scheller2, Aaron T Mayer3,4, Robert Negrin5, Sanjiv S Gambhir3,4, Surya Murty3,4, Ophir Vermesh3, Tomomi W Nobashi3, Juliane K Lohmeyer2, Toshihito Hirai2, Jeanette Baker2, Kenneth H Lau3.   

Abstract

Graft-versus-host disease (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), mediated primarily by donor T cells that become activated and attack host tissues. Noninvasive strategies detecting T-cell activation would allow for early diagnosis and possibly more effective management of HCT recipients. PET imaging is a sensitive and clinically relevant modality ideal for GvHD diagnosis, and there is a strong rationale for the use of PET tracers that can monitor T-cell activation and expansion with high specificity. The TNF receptor superfamily member OX40 (CD134) is a cell surface marker that is highly specific for activated T cells, is upregulated during GvHD, and mediates disease pathogenesis. We recently reported the development of an antibody-based activated T-cell imaging agent targeting OX40. In the present study, we visualize the dynamics of OX40 expression in an MHC-mismatch mouse model of acute GvHD using OX40-immunoPET. This approach enabled visualization of T-cell activation at early stages of disease, prior to overt clinical symptoms with high sensitivity and specificity. This study highlights the potential utility of the OX40 PET imaging as a new strategy for GvHD diagnosis and therapy monitoring. SIGNIFICANCE: OX40-immunoPET imaging is a promising noninvasive strategy for early detection of GvHD, capable of detecting signs of GvHD pathology even prior to the development of overt clinical symptoms. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32900772      PMCID: PMC8224961          DOI: 10.1158/0008-5472.CAN-20-1149

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.

Authors:  A Kotani; T Ishikawa; Y Matsumura; T Ichinohe; H Ohno; T Hori; T Uchiyama
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

2.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

3.  Imaging activated T cells predicts response to cancer vaccines.

Authors:  Israt S Alam; Aaron T Mayer; Idit Sagiv-Barfi; Kezheng Wang; Ophir Vermesh; Debra K Czerwinski; Emily M Johnson; Michelle L James; Ronald Levy; Sanjiv S Gambhir
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

4.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

Authors:  K R Cooke; L Kobzik; T R Martin; J Brewer; J Delmonte; J M Crawford; J L Ferrara
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

5.  18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

Authors:  C Bodet-Milin; M Lacombe; F Malard; E Lestang; X Cahu; P Chevallier; T Guillaume; J Delaunay; E Brissot; P Moreau; F Kraeber-Bodere; M Mohty
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

Review 6.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

7.  Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease.

Authors:  Catharina H M J Van Elssen; Mohammad Rashidian; Vladimir Vrbanac; Kai W Wucherpfennig; Zeina El Habre; Jana Sticht; Christian Freund; Johanne T Jacobsen; Juanjo Cragnolini; Jessica Ingram; Loes Plaisier; Eric Spierings; Andrew M Tager; Hidde L Ploegh
Journal:  J Nucl Med       Date:  2017-02-16       Impact factor: 10.057

8.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Authors:  Richard Tavaré; Helena Escuin-Ordinas; Stephen Mok; Melissa N McCracken; Kirstin A Zettlitz; Felix B Salazar; Owen N Witte; Antoni Ribas; Anna M Wu
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

9.  Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography.

Authors:  Matthias Stelljes; Sven Hermann; Jörn Albring; Gabriele Köhler; Markus Löffler; Christiane Franzius; Christopher Poremba; Verena Schlösser; Sarah Volkmann; Corinna Opitz; Christoph Bremer; Torsten Kucharzik; Gerda Silling; Otmar Schober; Wolfgang E Berdel; Michael Schäfers; Joachim Kienast
Journal:  Blood       Date:  2007-12-05       Impact factor: 22.113

10.  Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.

Authors:  Denis R Beckford Vera; Christof C Smith; Lisa M Bixby; Dylan M Glatt; Stuart S Dunn; Ryoichi Saito; William Y Kim; Jonathan S Serody; Benjamin G Vincent; Matthew C Parrott
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

View more
  7 in total

Review 1.  Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox.

Authors:  Chao Li; Chaozhe Han; Shao Duan; Ping Li; Israt S Alam; Zunyu Xiao
Journal:  J Nucl Med       Date:  2021-12-09       Impact factor: 10.057

2.  Whole-body PET Imaging of T-cell Response to Glioblastoma.

Authors:  Tomomi W Nobashi; Aaron T Mayer; Zunyu Xiao; Carmel T Chan; Aisling M Chaney; Michelle L James; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2021-09-21       Impact factor: 13.801

Review 3.  Probing immune infiltration dynamics in cancer by in vivo imaging.

Authors:  Thomas S C Ng; Harris H Allen; Mohammad Rashidian; Miles A Miller
Journal:  Curr Opin Chem Biol       Date:  2022-02-23       Impact factor: 8.972

4.  Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies.

Authors:  Jinghang Xie; Fadi El Rami; Kaixiang Zhou; Federico Simonetta; Zixin Chen; Xianchuang Zheng; Min Chen; Preethi B Balakrishnan; Sheng-Yao Dai; Surya Murty; Israt S Alam; Jeanette Baker; Robert S Negrin; Sanjiv S Gambhir; Jianghong Rao
Journal:  ACS Cent Sci       Date:  2022-05-12       Impact factor: 18.728

5.  MRI-based molecular imaging of epicardium-derived stromal cells (EpiSC) by peptide-mediated active targeting.

Authors:  Tamara Straub; Julia Nave; Pascal Bouvain; Mohammad Akbarzadeh; Siva Sai Krishna Dasa; Julia Kistner; Zhaoping Ding; Aseel Marzoq; Stefanie Stepanow; Katrin Becker; Julia Hesse; Karl Köhrer; Ulrich Flögel; Mohammad R Ahmadian; Brent A French; Jürgen Schrader; Sebastian Temme
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

Review 6.  Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.

Authors:  Alessia Volpe; Prasad S Adusumilli; Heiko Schöder; Vladimir Ponomarev
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

7.  Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.

Authors:  Federico Simonetta; Israt S Alam; Sanjiv S Gambhir; Robert S Negrin; Juliane K Lohmeyer; Bita Sahaf; Zinaida Good; Weiyu Chen; Zunyu Xiao; Toshihito Hirai; Lukas Scheller; Pujan Engels; Ophir Vermesh; Elise Robinson; Tom Haywood; Ataya Sathirachinda; Jeanette Baker; Meena B Malipatlolla; Liora M Schultz; Jay Y Spiegel; Jason T Lee; David B Miklos; Crystal L Mackall
Journal:  Clin Cancer Res       Date:  2020-10-21       Impact factor: 13.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.